• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Compass Pathways Takes Investors on a Trip to Higher Prices

Fresh off IPO, company sees mushrooming opportunity in psilocybin.
By DEBRA BORCHARDT
Sep 22, 2020 | 11:00 AM EDT
Stocks quotes in this article: CMPS, TLRY

Psychedelic company Compass Pathways PLC (CMPS)  got off to a stellar start of trading on Friday, as investors hungry for the next new thing bought up shares.

The U.K.-based mental health care company said on Friday that it had upped its initial public offering, and priced the shares at $17, which was higher than the expected range of $14 to $16 a share. The first trade was at 37.6% above the initial public offering price sending the stock to roughly $23. The stock was continuing to move higher and was lately selling at $29.

Initially the company was valued at $578 million, but the market cap eventually hit a billion. According to its prospectus, Compass reported total net losses of $13.2 million, $19.6 million and $24.8 million, respectively, for the fiscal years ended Dec. 31, 2018 and Dec. 31, 2019 and the six months ended June 30. Perhaps at some point investors will right size the market cap.

Compass had raised $116 million prior to its IPO. As of June 30, it had an accumulated deficit of $62.4 million. Its largest shareholder is Atai Life Sciences, which owns 29% of the stock. Other large shareholders include founders, George Goldsmith and Ekaterina Malievskaia, each with 16.5% of the company. Entities affiliated with Peter Thiel own 7.5%.

Psychedelic company stock traders will need to be extra cautious as this category has become very volatile with the rush to get into the early stages of the industry. Investors may recall that in 2018 when Tilray (TLRY)  went public, the stock trading had to be halted five times and shares briefly hit $300. Tilray shares now trade at $5.

Psilocybin Treatments for Depression

The company is known for its development of a new model of psilocybin therapy, in which psilocybin, a compound derived from a type of mushroom, is administered in conjunction with psychological support. This is not unlike the ketamine clinics, in which patients will take ketamine treatment under the guidance of a mental health professional.

"Our initial focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the current treatment paradigm," says the company in its overview. The company noted in its filing that early signals from academic studies, using formulations of psilocybin of other sources, have shown that psilocybin therapy "may have the potential to improve outcomes for patients suffering with depression, with rapid reductions in depression symptoms and effects lasting up to six months, after administration of a single high dose."

The company has targeted the depression market, which is seen as valued at $200 billion.

It also says that it has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, that it's calling COMP360. In 2019, it completed its first phase clinical trial, administering COMP360, along with psychological support, to 89 healthy volunteers, the largest randomized controlled clinical trial with psilocybin therapy to date, according to Compass Pathways. It found it was generally well-tolerated and is currently evaluating COMP360 in conjunction with psychological support in another trial.

That Phase IIb clinical trial consists of 216 patients suffering with TRD, in 20 sites across North America and Europe. This trial is investigating the safety and efficacy of COMP360 combined with psychological support, for the treatment of TRD, and aims to determine the optimal dose of COMP360. The trial is expected to yield results in late 2021.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no position in any of the stocks mentioned in this story.

TAGS: IPOs | Investing | Stocks | Biotechnology | Pharmaceuticals | Europe | Cannabis

More from Stocks

Trading Like It's 1999!

James "Rev Shark" DePorre
Jan 27, 2023 4:46 PM EST

The mood was bubbly as speculative investors piled into stocks with any minor exposure to Artificial Intelligence.

More Good Dividend Stocks With Pretty Charts

Bruce Kamich
Jan 27, 2023 1:31 PM EST

In this second part of a two-part series, we look at the final five of 10 stocks with the best of the both worlds.

Even Some Out of Fashion Names Are Now Back in Style

Jonathan Heller
Jan 27, 2023 12:30 PM EST

Sure, we're only one month in to 2023, but so far these stocks are starting the new year with a bang.

I'm Making Small Bets With These 2 Stocks

Bret Jensen
Jan 27, 2023 11:30 AM EST

While I remain cautious on the overall market, I continue to act upon the limited opportunities I'm finding in the current market.

Chevron Is Crushing It and for My Portfolio Too: Here's the Trade

Stephen Guilfoyle
Jan 27, 2023 10:51 AM EST

The only reason to exit the stock now is profit-taking.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:48 AM EST REAL MONEY

    Watch Doug Kass on the Daily Rundown!

    In today's Action Alerts PLUS Daily Rundown, Doug ...
  • 11:03 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend On Real Money

    It's time to start using this power to build great...
  • 03:06 PM EST BOB LANG

    LEAPS Webinar

    This week, I offered a free webinar session talkin...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login